Gilead and Arcus Biosciences established 10-year partnership to co-develop and co-commercialize next-generation cancer immunotherapies
On May 27, 2020, Gilead Sciences and Arcus Biosciences announced that the companies had entered into a 10-year…
-
-
Biotechnology | NIH | Oncology | Therapeutics
Roswell Park’s Dr. Pawel Kalinski lead $14.5 million NCI-funded immunotherapy effort
On Apr. 16, 2020, a team led by Pawel Kalinski, MD, PhD, of Roswell Park Comprehensive Cancer Center…
-
CSL Behring and SAB Biotherapeutics joined forces to deliver new potential COVID-19 therapeutic
On Apr. 8, 2020, CSL Behring and SAB Biotherapeutics announced a partnership to combat the coronavirus pandemic with…
-
La Jolla Institute for Immunology hosted coronavirus immunotherapy clearinghouse
On Mar. 30, 2020, the La Jolla Institute for Immunology (LJI) announced it had been awarded a $1.73…
-
The Jackson Laboratory received $2.5 million from The Mark Foundation for breakthrough cancer immunotherapy project
On Dec. 18, 2019, the Jackson Laboratory received $2.5 million from The Mark Foundation for breakthrough cancer immunotherapy…
-
Pediatric brain tumor treatment at the University of Alabama awarded FDA grant for first-in-human study
On Dec. 17, 2019, the University of Alabama at Birmingham Comprehensive Cancer Center (UAB) announced that Gregory Friedman,…
-
The Cancer Prevention and Research Institute of Texas awarded 10 new recruitment grants
On Nov. 20, 2019, the Cancer Prevention and Research Institute of Texas (CPRIT) announced the recruitment of its…
-
Celgene acquired by Bristol-Myers Squibb
On Nov. 20, 2019, Bristol-Myers announced that it had completed its acquisition of Celgene following the receipt of…
-
The Masonic Cancer Center and the University of Minnesota opened a first-in-human clinical trial for treatment of advanced solid tumors
On Oct. 2, 2019, the Masonic Cancer Center and the University of Minnesota (UM) opened a new first-in-human…
-
Pascal Biosciences discovered cannabinoids activate the major histocompatibility complex to aid cancer treatment
On Sept. 23, 2019, Pascal Biosciences identified specific cannabinoids that enhance the immunogenicity of tumor cells, rendering them…
-
Penn received a $12 million grant to study the connection between cellular therapies and new methods of radiation therapy
On Jun. 3, 2019, the University of Pennsylvania (Penn) announced it had received a $12 million grant from…
-
CPRIT researcher James P Allison was awarded the 2018 Nobel Prize in physiology or medicine jointly with Tasuku Honjo
On Oct. 1, 2018, James P. Allison, a native of Alice, Texas, son of a country doctor, and…
-
NIH partners with leading companies to accelerate development of cancer immunotherapies
On Oct. 12, 2017, the NIH and 11 leading biopharmaceutical companies launched the Partnership for Accelerating Cancer Therapies…
-
Bezos family donated $35 million to Fred Hutch
On Mar. 30, 2017, the Fred Hutchinson Cancer Research Center announced that the Bezos family had donated $35…
-
PharmAthene and Altimmune announced merger to create immunotherapeutics company targeting infectious diseases
On Jan. 19, 2017, PharmAthene and Altimmune, a privately-held immunotherapeutics company targeting infectious diseases, announced an agreement for…
-
Fred Hutch opened first-of-its kind Bezos Family Immunotherapy Clinic
On Nov. 1, 2016, the Fred Hutchinson Cancer Research Center announced the opening of the Bezos Family Immunotherapy…
-
$10 million gift created Bursky Center for Human Immunology and Immunotherapy
On Sept. 26, 2016, Washington University School of Medicine in St. Louis announced it had received a $10…
-
Parker Institute Commits Additional $125 Million for Audacious Mission to Cure Cancer
On Jul. 18, 2024, the Parker Institute for Cancer Immunotherapy announced a $125 million investment to expand its…
-
The Bloomberg-Kimmel Institute for Cancer Immunotherapy was founded
On Mar. 29, 2016, Johns Hopkins University announced gifts totaling $125 million to create a cancer research institute…
-
Bezos family donated $20 million to the Fred Hutch to develop therapies that ‘melt’ cancer
On Apr. 7, 2014, the Fred Hutchinson Cancer Research Center announced that the Bezos family had committed $20…
-
Biotechnology | FDA | Oncology | Therapeutics
PROVENGE was approved by the FDA
On Apr. 29, 2010, the FDA approved sipuleucel-T (PROVENGE), made by the Dendreon, an autologous cellular immunotherapy for…
-
Biotechnology | HIV | NIH | Oncology
National Cancer Institute researchers replace a patient’s immune system with cancer-fighting cells
On Sept. 19, 2002, a new approach to cancer treatment that replaced a patient’s immune system with cancer-fighting…
-
Dendreon Corporation launched its Initial Public Offering
On Jun. 16, 2000, Dendreon announced its initial public offering of 4,500,000 shares of common stock at $10.00…
-
Penn Medicine’s Cancer Center was renamed the Abramson Cancer Center of the University of Pennsylvania
In 1997, the Penn Medicine’s Cancer Center was renamed the Abramson Cancer Center of the University of Pennsylvania…
-
Dendreon Corporation was founded
In 1992, Dendreon was founded, and its lead product, Provenge, was an immunotherapy for prostate cancer. Dendreon filed…
-
The O’Neal Comprehensive Cancer Center at University of Alabama was founded
In 1971, the University of Alabama at Birmingham Comprehensive Cancer Center (UAB) was founded and received its NCI…
